KEGG   PATHWAY: dro05330
dro05330                    Pathway                                

Allograft rejection - Desmodus rotundus (common vampire bat)
Allograft rejection is the consequence of the recipient's alloimmune response to nonself antigens expressed by donor tissues. After transplantation of organ allografts, there are two pathways of antigen presentation. In the direct pathway, recipient T cells react to intact allogeneic MHC molecules expressed on the surface of donor cells. This pathway would activate host CD4 or CD8 T cells. In contrast, donor MHC molecules (and all other proteins) shed from the graft can be taken up by host APCs and presented to recipient T cells in the context of self-MHC molecules - the indirect pathway. Such presentation activates predominantly CD4 T cells. A direct cytotoxic T-cell attack on graft cells can be made only by T cells that recognize the graft MHC molecules directly. Nontheless, T cells with indirect allospecificity can contribute to graft rejection by activating macrophages, which cause tissue injury and fibrosis, and are also likely to be important in the development of an alloantibody response to graft.
Human Diseases; Immune disease
Pathway map
dro05330  Allograft rejection

Desmodus rotundus (common vampire bat) [GN:dro]
112297492  RLA class I histocompatibility antigen, alpha chain 11/11-like [KO:K06751]
112313872  patr class I histocompatibility antigen, alpha chain E-like [KO:K06751]
112313873  patr class I histocompatibility antigen, A-2 alpha chain-like [KO:K06751]
112313875  patr class I histocompatibility antigen, A-126 alpha chain-like [KO:K06751]
112313876  patr class I histocompatibility antigen, B-1 alpha chain-like [KO:K06751]
112313879  LOW QUALITY PROTEIN: HLA class I histocompatibility antigen, B-39 alpha chain-like [KO:K06751]
112313880  HLA class I histocompatibility antigen, B-15 alpha chain-like [KO:K06751]
112314045  HLA class I histocompatibility antigen, A-36 alpha chain-like isoform X1 [KO:K06751]
112314059  saoe class I histocompatibility antigen, A alpha chain-like isoform X1 [KO:K06751]
112314061  patr class I histocompatibility antigen, A-126 alpha chain-like isoform X1 [KO:K06751]
112314062  HLA class I histocompatibility antigen, B-48 alpha chain-like [KO:K06751]
112314063  patr class I histocompatibility antigen, A-126 alpha chain-like [KO:K06751]
112314064  patr class I histocompatibility antigen, A-126 alpha chain-like [KO:K06751]
112302342  patr class I histocompatibility antigen, A-126 alpha chain-like [KO:K06751]
112302447  H-2 class I histocompatibility antigen, Q9 alpha chain-like [KO:K06751]
112302469  patr class I histocompatibility antigen, A-126 alpha chain-like [KO:K06751]
112320475  CD80; T-lymphocyte activation antigen CD80 [KO:K05412]
112320646  CD86; T-lymphocyte activation antigen CD86 [KO:K05413]
112307972  CD28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
112304655  IL12A; interleukin-12 subunit alpha [KO:K05406]
112319648  IL12B; interleukin-12 subunit beta [KO:K05425]
112297049  FASLG; tumor necrosis factor ligand superfamily member 6 [KO:K04389]
112307358  FAS; tumor necrosis factor receptor superfamily member 6 [KO:K04390]
112305296  PRF1; perforin-1 [KO:K07818]
112296490  granzyme B-like [KO:K01353] [EC:]
112296591  granzyme H-like [KO:K01353] [EC:]
112302159  DLA class II histocompatibility antigen, DR-1 beta chain-like [KO:K06752]
112302160  SLA class II histocompatibility antigen, DQ haplotype D alpha chain-like [KO:K06752]
112302240  HLA class II histocompatibility antigen, DM beta chain isoform X1 [KO:K06752]
112302328  HLA class II histocompatibility antigen, DR alpha chain [KO:K06752]
112302354  HLA class II histocompatibility antigen, DM alpha chain [KO:K06752]
112312503  IL2; interleukin-2 [KO:K05429]
112307303  CD40LG; CD40 ligand isoform X1 [KO:K03161]
112304112  CD40; tumor necrosis factor receptor superfamily member 5 [KO:K03160]
112319176  IFNG; interferon gamma [KO:K04687]
112302067  TNF; tumor necrosis factor isoform X1 [KO:K03156]
112318159  IL4; interleukin-4 [KO:K05430]
112318060  IL5; LOW QUALITY PROTEIN: interleukin-5 [KO:K05428]
112315005  IL10; interleukin-10 [KO:K05443]
C00533  Nitric oxide
Arakelov A, Lakkis FG.
The alloimmune response and effector mechanisms of allograft rejection.
Semin Nephrol 20:95-102 (2000)
Le Moine A, Goldman M, Abramowicz D.
Multiple pathways to allograft rejection.
Transplantation 73:1373-81 (2002)
Trivedi HL.
Immunobiology of rejection and adaptation.
Transplant Proc 39:647-52 (2007)
Pietra BA.
Transplantation immunology 2003: simplified approach.
Pediatr Clin North Am 50:1233-59 (2003)
Oka T, Yoshimura N.
Immunosuppression in organ transplantation.
Jpn J Pharmacol 71:89-100 (1996)
Sayegh MH.
Why do we reject a graft? Role of indirect allorecognition in graft rejection.
Kidney Int 56:1967-79 (1999)
Benichou G.
Direct and indirect antigen recognition: the pathways to allograft immune rejection.
Front Biosci 4:D476-80 (1999)
Turvey SE, Wood KJ.
Immunobiology of solid organ transplantation.
Int Surg 84:279-90 (1999)
Janeway CA, Travers P, Walport M, Shlomchik MJ.
Immunobiology 6th edition
Garland Science Publishing (2005)
Game DS, Lechler RI.
Pathways of allorecognition: implications for transplantation tolerance.
Transpl Immunol 10:101-8 (2002)
Lechler RI, Garden OA, Turka LA.
The complementary roles of deletion and regulation in transplantation tolerance.
Nat Rev Immunol 3:147-58 (2003)
dro04210  Apoptosis
dro04514  Cell adhesion molecules
dro04610  Complement and coagulation cascades
dro04612  Antigen processing and presentation
dro04660  T cell receptor signaling pathway
dro04662  B cell receptor signaling pathway
KO pathway

DBGET integrated database retrieval system